Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2025)

Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Protalix Biotherapeutics (NYSEMKT:PLX) is the #1 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Protalix Biotherapeutics (NYSEMKT:PLX) is: Value: B, Growth: A, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: B.

Protalix Biotherapeutics (NYSEMKT:PLX) has a Due Diligence Score of 23, which is -1 points lower than the biotech industry average of 24. Although this number is below the industry average, our proven quant model rates PLX as a "A".

PLX passed 7 out of 33 due diligence checks and has weak fundamentals. Protalix Biotherapeutics has seen its stock return 147.93% over the past year, overperforming other biotech stocks by 225 percentage points.

Protalix Biotherapeutics has an average 1 year price target of $15.00, an upside of 400% from Protalix Biotherapeutics's current stock price of $3.00.

Protalix Biotherapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Protalix Biotherapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #2 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 57, which is 33 points higher than the biotech industry average of 24.

AUPH passed 19 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 57.69% over the past year, overperforming other biotech stocks by 135 percentage points.

Catalyst Pharmaceuticals (NASDAQ:CPRX) is the #3 top biotech stock out of 661 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Catalyst Pharmaceuticals (NASDAQ:CPRX) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: D, Financials: A, and AI: B.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a Due Diligence Score of 76, which is 52 points higher than the biotech industry average of 24.

CPRX passed 25 out of 33 due diligence checks and has strong fundamentals. Catalyst Pharmaceuticals has seen its stock return 59.67% over the past year, overperforming other biotech stocks by 137 percentage points.

Catalyst Pharmaceuticals has an average 1 year price target of $33.20, an upside of 36.79% from Catalyst Pharmaceuticals's current stock price of $24.27.

Catalyst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Catalyst Pharmaceuticals, 60% have issued a Strong Buy rating, 40% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 6.27%, which is 4 percentage points higher than the biotech industry average of 1.81%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.46%, which is 1 percentage points higher than the biotech industry average of 1.81%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.5% indicates that its dividend yield is sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.32%, which is the same as the biotech industry average of 1.81%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 43.8% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were down -0.68% in the last day, and up 1.97% over the last week. Arvinas was the among the top losers in the biotechnology industry, dropping -24.84% yesterday.

Arvinas shares are trading lower. The company reported Q1 financial results.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Puma Biotechnology (NASDAQ:PBYI) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -37.78% in the past year. It has overperformed other stocks in the biotech industry by 39 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -1.35% in the past year. It has overperformed other stocks in the biotech industry by 76 percentage points.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Jazz Pharmaceuticals has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Jazz Pharmaceuticals's stock has gained 6.23% in the past year. It has overperformed other stocks in the biotech industry by 83 percentage points.

54.79% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 102% over the next year.

1.74% of biotech stocks have a Zen Rating of A (Strong Buy), 4.13% of biotech stocks are rated B (Buy), 42.39% are rated C (Hold), 35.87% are rated D (Sell), and 15.87% are rated F (Strong Sell).